Literature DB >> 32845561

Self-Assembled Peptide-Based Biocomposites for Near-Infrared Light Triggered Drug Release to Tumor Cells.

Rachel E Daso1, Ipsita A Banerjee1.   

Abstract

Peptide-based nanomaterials are increasingly gaining popularity due to their specificity, biocompatibility, and biodegradability. In this work, a new multi-layered peptide-based biocomposite for targeting MCF-7 breast cancer cells is developed. The amphipathic Fluorenylmethyloxycarbonyl (Fmoc)-Leu-Ser peptide is synthesized, which is conjugated to a tumor-targeting peptide sequence Gly-Cys-Gly-Asn-Ser to form Fmoc-L-S-G-C-G-N-S (FLS) assemblies. To the FLS assemblies, gold nanorods are then attached to develop drug delivery vehicles (DDVs). The DDVs are entrapped with the anti-cancer drug fulvestrant. Entrapment efficiency is found to be 50.6%. Release studies indicate that irradiating the gold nanorod bound DDVs at NIR wavelength (785 nm) increases drug release by fourfold compared to assemblies that are not irradiated. These results also show higher cytotoxicity and lower cell invasion due to photo-triggered drug release. Furthermore, distinct actin cytoskeletal changes are observed. Such novel peptide-based gold nanorod bound DDVs demonstrate potential in dual targeting of MCF-7 breast cancer cells.
© 2020 Wiley-VCH GmbH.

Entities:  

Keywords:  bio-organic; drug delivery; gold nanorods; peptide nanostructures; tumor targeting

Year:  2020        PMID: 32845561      PMCID: PMC7673930          DOI: 10.1002/biot.202000128

Source DB:  PubMed          Journal:  Biotechnol J        ISSN: 1860-6768            Impact factor:   4.677


  20 in total

1.  The molecular basis of Goodpasture and Alport syndromes: beacons for the discovery of the collagen IV family.

Authors:  Billy G Hudson
Journal:  J Am Soc Nephrol       Date:  2004-10       Impact factor: 10.121

Review 2.  Alport syndrome--clinical phenotypes, incidence, and pathology.

Authors:  M C Gregory; D A Terreros; D F Barker; P N Fain; J C Denison; C L Atkin
Journal:  Contrib Nephrol       Date:  1996       Impact factor: 1.580

3.  Glomerular basement membrane. Identification of a novel disulfide-cross-linked network of alpha3, alpha4, and alpha5 chains of type IV collagen and its implications for the pathogenesis of Alport syndrome.

Authors:  S Gunwar; F Ballester; M E Noelken; Y Sado; Y Ninomiya; B G Hudson
Journal:  J Biol Chem       Date:  1998-04-10       Impact factor: 5.157

Review 4.  Genetics of classic Alport's syndrome.

Authors:  F A Flinter; J S Cameron; C Chantler; I Houston; M Bobrow
Journal:  Lancet       Date:  1988-10-29       Impact factor: 79.321

5.  Structure of the human type IV collagen gene COL4A3 and mutations in autosomal Alport syndrome.

Authors:  Laurence Heidet; Christelle Arrondel; Lionel Forestier; Lola Cohen-Solal; Geraldine Mollet; Bruno Gutierrez; Christophoros Stavrou; Marie Claire Gubler; Corinne Antignac
Journal:  J Am Soc Nephrol       Date:  2001-01       Impact factor: 10.121

Review 6.  Molecular genetics of Alport syndrome.

Authors:  K Tryggvason; J Zhou; S L Hostikka; T B Shows
Journal:  Kidney Int       Date:  1993-01       Impact factor: 10.612

7.  Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.

Authors:  Sue Richards; Nazneen Aziz; Sherri Bale; David Bick; Soma Das; Julie Gastier-Foster; Wayne W Grody; Madhuri Hegde; Elaine Lyon; Elaine Spector; Karl Voelkerding; Heidi L Rehm
Journal:  Genet Med       Date:  2015-03-05       Impact factor: 8.822

8.  Clinical utility gene card for: Alport syndrome - update 2014.

Authors:  Jens Michael Hertz; Mads Thomassen; Helen Storey; Frances Flinter
Journal:  Eur J Hum Genet       Date:  2014-11-12       Impact factor: 4.246

9.  Whole exome sequencing reveals novel COL4A3 and COL4A4 mutations and resolves diagnosis in Chinese families with kidney disease.

Authors:  Fujun Lin; Fan Bian; Jun Zou; Xiangru Wu; Jianping Shan; Wei Lu; Yao Yao; Gengru Jiang; Daniel Philip Gale
Journal:  BMC Nephrol       Date:  2014-11-07       Impact factor: 2.388

10.  Unbiased next generation sequencing analysis confirms the existence of autosomal dominant Alport syndrome in a relevant fraction of cases.

Authors:  C Fallerini; L Dosa; R Tita; D Del Prete; S Feriozzi; G Gai; M Clementi; A La Manna; N Miglietti; R Mancini; G Mandrile; G M Ghiggeri; G Piaggio; F Brancati; L Diano; E Frate; A R Pinciaroli; M Giani; P Castorina; E Bresin; D Giachino; M De Marchi; F Mari; M Bruttini; A Renieri; F Ariani
Journal:  Clin Genet       Date:  2013-10-17       Impact factor: 4.438

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.